keyword
MENU ▼
Read by QxMD icon Read
search

Breast endocrine surgery

keyword
https://www.readbyqxmd.com/read/28712671/analysis-of-stereotactic-biopsies-performed-on-suspicious-calcifications-identified-within-24-months-after-completion-of-breast-conserving-surgery-and-radiation-therapy-for-early-breast-cancer-can-biopsy-be-obviated
#1
Rosalind P Candelaria, Palita Hansakul, Alastair M Thompson, Huong Le-Petross, Vicente Valero, Roland Bassett, Monica L Huang, Lumarie Santiago, Beatriz E Adrada
BACKGROUND: To determine the cancer yield of stereotactic biopsy of suspicious calcifications identified within 24 months after breast conservation therapy (BCT). METHODS: Retrospective review of stereotactic biopsies performed during 2009-2013 for suspicious calcifications in the ipsilateral breast of patients who completed BCT. RESULTS: 94/2773 (3.4%) had stereotactic biopsies for suspicious calcifications in the ipsilateral breast; 7/94 (7...
July 1, 2017: American Journal of Surgery
https://www.readbyqxmd.com/read/28702891/predictors-associated-with-mri-surveillance-screening-in-women-with-a-personal-history-of-unilateral-breast-cancer-but-without-a-genetic-predisposition-for-future-contralateral-breast-cancer
#2
John V Hegde, Xiaoyan Wang, Deanna J Attai, Maggie L DiNome, Amy Kusske, Anne C Hoyt, Sara A Hurvitz, Joanne B Weidhaas, Michael L Steinberg, Susan A McCloskey
PURPOSE: For women with a personal history of breast cancer (PHBC), no validated mechanisms exist to calculate future contralateral breast cancer (CBC) risk. The Manchester risk stratification guidelines were developed to evaluate CBC risk in women with a PHBC, primarily for surgical decision making. This tool may be informative for the use of MRI screening, as CBC risk is an assumed consideration for high-risk surveillance. METHODS: Three hundred twenty-two women with a PHBC were treated with unilateral surgery within our multidisciplinary breast clinic...
July 12, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28698832/acute-inflammatory-response-during-neoadjuvant-chemotherapy-for-locally-advanced-breast-cancer-a-case-report
#3
Xiaolan Feng, Tanya Berrang, John Paul McGhie, Peter Watson, R Petter Tonseth, Pauline T Truong
We report on a 56-year-old Caucasian female, diagnosed with locally advanced, hormone-receptor-positive, and human epidermal growth factor receptor 2 (HER2)-positive cancer of the left breast. The patient received neoadjuvant chemotherapy with adriamycin/cyclophosphamide (AC) followed by docetaxel/trastuzumab. A partial clinical and radiographical response was documented after four cycles of AC. Approximately one week after the first cycle of docetaxel and trastuzumab, the patient presented with diffuse edema, erythema, and induration involving the entire left breast...
June 10, 2017: Curēus
https://www.readbyqxmd.com/read/28697858/accelerated-partial-breast-irradiation-for-elderly-women-with-early-breast-cancer-a-compromise-between-whole-breast-irradiation-and-omission-of-radiotherapy
#4
Shakeel Sumodhee, Johan Levy, Emmanuel Chamorey, Daniel Lam Cham Kee, Marie-Eve Chand, Mathieu Gautier, Isabelle Peyrottes, Emmanuel Barranger, Jean-Michel Hannoun-Levi
PURPOSE: Regarding adjuvant radiation therapy making decision for elderly women, Albert (2013) published a nomogram predicting the mastectomy-free survival (MFS) rate with or without adjuvant irradiation. Based on this approach, we proposed to investigate the use of accelerated partial breast irradiation (APBI) vs. whole breast irradiation (WBI) or endocrine therapy alone in elderly low-risk breast cancer patients. METHODS AND MATERIALS: For each elderly woman treated by conserving surgery and APBI (multicatheter interstitial high-dose-rate brachytherapy), 5- and 10-year MFS rates were calculated...
July 8, 2017: Brachytherapy
https://www.readbyqxmd.com/read/28696086/pregnancy-after-breast-cancer-hope-after-the-storm
#5
Valeria DE Simone, Olivia Pagani
INTRODUCTION: In the last decades, long-term outcomes of young women with breast cancer have greatly improved, raising several new survivorship needs which include fertility preservation and pregnancy. The prejudice against pregnancy after breast cancer is still alive among different healthcare providers (e.g. gynecologists, oncologists, general practitioners) and women are often confused and left alone in their family decision planning. EVIDENCE ACQUISITION AND SYNTHESIS: All the available retrospective data confirm pregnancy after breast cancer is safe both for the mother and the offspring, also in women with hormone receptor positive disease...
July 10, 2017: Minerva Ginecologica
https://www.readbyqxmd.com/read/28690652/prognostic-impact-of-progesterone-receptor-status-in-chinese-estrogen-receptor-positive-invasive-breast-cancer-patients
#6
Nan Yao, Zhenchuan Song, Xinle Wang, Shan Yang, Heng Song
PURPOSE: Estrogen receptor (ER) and progesterone receptor (PR) have been used as indicators of endocrine system status since the mid-1970s in the clinical management of breast cancer. The predictive role of ER in endocrine therapy is undisputed, but the prognostic value of PR is still debated. The aim of this study was to investigate the clinical characteristics and prognosis of ER positive breast cancer with different PR expression levels. METHODS: A population cohort of 3,030 primary invasive ER positive breast cancer patients from a single cancer center underwent surgery and received adjuvant endocrine therapy from 2004 to 2010...
June 2017: Journal of Breast Cancer
https://www.readbyqxmd.com/read/28669712/lessons-in-precision-oncology-from-neoadjuvant-endocrine-therapy-trials-in-er-breast-cancer
#7
Matthew J Ellis
For post-menopausal women with clinical stage II/III estrogen receptor positive (ER+) breast cancer neoadjuvant endocrine therapy (NET) is an under-utilized and low-toxicity alternative to chemotherapy for increasing breast conservation rates. Individual responses to endocrine therapy can also be used to tailor systemic treatment. The Preoperative Endocrine Prognostic Index (PEPI) was developed to identify patients at low risk of relapse after NET so that adjuvant chemotherapy can safely be avoided. In a recent validation study, patients with pathological stage 1 or 2A breast cancers with a Ki67 value of 2...
June 29, 2017: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/28654365/treatment-efficacy-adherence-and-quality-of-life-among-women-younger-than-35-years-in-the-international-breast-cancer-study-group-text-and-soft-adjuvant-endocrine-therapy-trials
#8
Poornima Saha, Meredith M Regan, Olivia Pagani, Prudence A Francis, Barbara A Walley, Karin Ribi, Jürg Bernhard, Weixiu Luo, Henry L Gómez, Harold J Burstein, Vani Parmar, Roberto Torres, Josephine Stewart, Meritxell Bellet, Antonia Perelló, Faysal Dane, Antonio Moreira, Daniel Vorobiof, Michelle Nottage, Karen N Price, Alan S Coates, Aron Goldhirsch, Richard D Gelber, Marco Colleoni, Gini F Fleming
Purpose To describe benefits and toxicities of adjuvant endocrine therapies in women younger than 35 years with breast cancer (n = 582) enrolled in the Suppression of Ovarian Function Trial (SOFT) and Tamoxifen and Exemestane Trial (TEXT). Methods In SOFT, women still premenopausal after surgery with or without chemotherapy were randomly assigned to tamoxifen alone, tamoxifen plus ovarian function suppression (OFS), or exemestane plus OFS. In TEXT, all received OFS with or without concomitant chemotherapy and were randomly assigned to exemestane plus OFS or tamoxifen plus OFS...
June 27, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28636294/-selective-therapeutic-de-escalation-in-early-stage-breast-cancer
#9
Aikaterini Liapi, Apostolos Sarivalasis, Wendy Jeanneret Sozzi, Loïc Lelièvre, Khalil Zaman
The survival of patients with breast cancer has improved considerably thanks to adjuvant radiotherapy and systemic treatments. Due to the potential adverse events associated with these treatments, a de-escalation effort was undertaken concerning surgery and more recently the adjuvant treatments. Conservative breast surgery and the avoidance of axillary dissection were possible for the majority of the patients without detrimental effect on survival. New radiotherapy techniques and the consideration of cancer biology allowed to better protect the peripheral organs and even to avoid treatment in certain low-risk patients...
May 17, 2017: Revue Médicale Suisse
https://www.readbyqxmd.com/read/28592759/primary-breast-diffuse-large-b-cell-lymphoma-in-a-male
#10
Kiyonobu Tokuyama, Yasuaki Uemoto, Satoshi Kitagawa, Haruhiko Ohashi
A 74-year-old male with a mass in the right breast visited the Department of Breast and Endocrine Surgery in November 20XX. Core needle biopsy was performed. Pathological diagnosis was diffuse large B-cell lymphoma. The Ann Arbor clinical stage was IIA, and international prognostic index was low-intermediate. Six courses of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone and four courses of intrathecal chemotherapy were administered, and the patient achieved complete remission.
2017: [Rinshō Ketsueki] the Japanese Journal of Clinical Hematology
https://www.readbyqxmd.com/read/28585885/validity-of-danish-breast-cancer-group-dbcg-registry-data-used-in-the-predictors-of-breast-cancer-recurrence-probecare-premenopausal-breast-cancer-cohort-study
#11
Deirdre P Cronin-Fenton, Anders Kjærsgaard, Thomas P Ahern, Marco Mele, Marianne Ewertz, Stephen Hamilton-Dutoit, Peer M Christiansen, Bent Ejlertsen, Henrik T Sørensen, Timothy L Lash, Rebecca A Silliman
BACKGROUND: Validation studies of the Danish Breast Cancer Group (DBCG) registry show good agreement with medical records for adjuvant treatment data, but inconsistent recurrence information. No studies have validated changes in menopausal status or endocrine therapy during follow-up. In a longitudinal study, we validated DBCG data using medical records as the gold standard. MATERIAL AND METHODS: From a cohort of 5959 premenopausal women diagnosed during 2002-2010 with stage I-III breast cancer, we selected 151 patients - 77 estrogen-receptor-positive and 74 estrogen-receptor-negative - from three hospitals...
June 6, 2017: Acta Oncologica
https://www.readbyqxmd.com/read/28585003/secondary-breast-carcinoma-after-completely-remitted-chronic-myeloid-leukemia-following-targeted-tyrosine-kinase-inhibitor-therapy
#12
Linlin Pan, Junwu Duan, Weiqiang Qiao, Lirong Bi, Di Wu, Zhimin Fan, Ming Yang
We describe a rare case of secondary breast carcinoma after chronic myeloid leukemia (CML) in a 56-year-old woman. The patient was treated with hydroxyurea and imatinib for CML and achieved complete remission (she has since been taking imatinib as the maintenance therapy). Four years later, the patient noticed a firm and painless lump in the left breast, which was diagnosed as ductal carcinoma in situ based on a percutaneous biopsy of the mass. Simple resection and sentinel lymph node biopsy of the left breast were then performed...
June 5, 2017: Breast Cancer: the Journal of the Japanese Breast Cancer Society
https://www.readbyqxmd.com/read/28562530/adjuvant-endocrine-therapy-alone-in-patients-with-node-positive-luminal-a-type-breast-cancer
#13
COMPARATIVE STUDY
Sungmin Park, Se Kyung Lee, Hyun-June Paik, Jai Min Ryu, Isaac Kim, Soo Youn Bae, Jonghan Yu, Seok Won Kim, Jeong Eon Lee, Seok Jin Nam
Luminal A breast cancer has a much better prognosis than other subtypes, with a low risk of local or regional recurrence. However, there is controversy around under- versus overtreatment with regard to adjuvant treatment of node-positive, luminal A breast cancer. The purpose of this study was to identify whether adjuvant systemic chemotherapy has any benefit in node-positive, luminal A breast cancer and to evaluate feasibility of endocrine therapy without chemotherapy in this group.This was a retrospective study of 11,025 patients who were surgically treated for invasive breast cancer at Samsung Medical Center between January 2004 and December 2013...
June 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28526959/adjuvant-tamoxifen-but-not-aromatase-inhibitor-therapy-decreases-serum-levels-of-the-wnt-inhibitor-dickkopf-1-while-not-affecting-sclerostin-in-breast-cancer-patients
#14
Andy Göbel, Jan D Kuhlmann, Theresa Link, Pauline Wimberger, Andrew J Browne, Martina Rauner, Lorenz C Hofbauer, Tilman D Rachner
PURPOSE: Endocrine therapies, including tamoxifen or aromatase inhibitors, are indispensable for the treatment of patients with estrogen receptor (ER)- and/or progesterone-positive breast cancer. Whereas tamoxifen displays partial ER agonistic effects in bone, aromatase inhibitors increase bone resorption and fracture risk. The Wnt inhibitors dickkopf-1 (DKK-1) and sclerostin negatively impact bone formation and are considered targets for the treatment of bone disorders. However, the effect of endocrine therapies on serum DKK-1 and sclerostin levels in patients with primary breast cancer remains elusive...
May 19, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28516441/decision-making-in-the-surgical-management-of-invasive-breast-cancer-part-2-expanded-applications-for-breast-conserving-surgery
#15
REVIEW
Lisa A Newman
Treatment of early-stage invasive breast cancer with breast-conserving surgery plus radiation therapy (RT) yields overall survival outcomes equivalent to those achieved with mastectomy. Further, breast-conserving surgery is endorsed by the National Comprehensive Cancer Network as being supported by the highest-level, category 1 evidence. Advances in pathologic evaluation, management of multiple tumors, oncoplastic lumpectomy techniques, neoadjuvant chemotherapy, and hypofractionated RT can expand the pool of patients eligible for breast-conserving surgery...
May 15, 2017: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/28511371/study-of-serum-total-psa-and-free-psa-as-an-oncological-marker-in-breast-tumour
#16
Elteza Tahjiba Jahir, Runi Devi, Bibhuti Bhushan Borthakur
INTRODUCTION: Breast Cancer (BC) cases are rising alarmingly all over the world and India is not an exception. This rising trend is due to an increased age at first child birth, decreased breast feeding, and the changing lifestyle mostly in urban India. With the advent of more sensitive methodologies and research works in this field, it has been suggested that Prostate Specific Antigen (PSA) plays an important role in the pathogenesis of breast cancer besides other established tumour markers...
March 2017: Journal of Clinical and Diagnostic Research: JCDR
https://www.readbyqxmd.com/read/28509627/impact-of-risk-reducing-salpingo-oophorectomy-in-premenopausal-women
#17
R F M Vermeulen, M van Beurden, C M Korse, G G Kenter
OBJECTIVES: To describe implications of premenopausal risk-reducing salpingo-oophorectomy (RRSO) on quality of life, endocrine symptoms, sexual function, osteoporosis, cardiovascular health, metabolic syndrome, cognitive impairment and safety of hormone replacement therapy. METHODS: We searched the following electronic databases: The Cochrane Library, EMBASE, PsycInfo, and MEDLINE. We selected controlled and uncontrolled trials of premenopausal women undergoing RRSO...
June 2017: Climacteric: the Journal of the International Menopause Society
https://www.readbyqxmd.com/read/28491135/highlights-from-the-15th-st-gallen-international-breast-cancer-conference-15-18-march-2017-vienna-tailored-treatments-for-patients-with-early-breast-cancer
#18
Consuelo Morigi
The 15th St Gallen International Breast Cancer Conference was held in Vienna for the second time, from 15th-18th March 2017. 4000 people from 105 countries all over the world were invited to take part in the event. The real highlight of the conference was the last day with the International Consensus Session which was chaired by around 50 experts on breast cancer worldwide. With reference to data from scientific research, the consensus panel tried to offer guidelines for the management of breast cancer with the aim of providing patients with optimal treatment...
2017: Ecancermedicalscience
https://www.readbyqxmd.com/read/28475932/therapeutic-escalation-de-escalation-data-from-15-508-early-breast-cancer-treated-with-upfront-surgery-and-sentinel-lymph-node-biopsy-slnb
#19
Gilles Houvenaeghel, Eric Lambaudie, Monique Cohen, Jean-Marc Classe, Fabien Reyal, Jean-Rémy Garbay, Sylvia Giard, Nicolas Chopin, Alejandra Martinez, Roman Rouzier, Emile Daraï, Pierre Emmanuel Colombo, Charles Coutant, Pierre Gimbergues, Pierre Azuar, Richard Villet, Christine Tunon de Lara, Emmanuel Barranger, Laura Sabiani, Anthony Goncalves
INTRODUCTION: The aim of this study was to examine changes in therapeutic practices for early breast cancer T0-2 N0 managed by upfront surgery and SLNB. POPULATION: Between 1999 and 2012, 15.508 patients were treated. Four periods were determined: 1999-2003, 2004-2006, 2007-2009 and > 2009. Five tumor subtypes were defined according to hormonal receptors (HR) and Her2: Luminal A (HR + Her2- Grade 1-2), Her2 (Her2+ HR-), Triple-negative (HR- Her2-), Luminal B Her2- (HR + Her2- Grade 3), Luminal B Her2+ (HR + HER2+)...
August 2017: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/28466123/the-role-of-quantitative-estrogen-receptor-status-in-predicting-tumor-response-at-surgery-in-breast-cancer-patients-treated-with-neoadjuvant-chemotherapy
#20
REVIEW
Jacques Raphael, Sonal Gandhi, Nim Li, Fang-I Lu, Maureen Trudeau
PURPOSE: Estrogen receptor (ER) negative (-) breast cancer (BC) patients have better tumor response rates than ER-positive (+) patients after neoadjuvant chemotherapy (NCT). We conducted a retrospective review using the institutional database "Biomatrix" to assess the value of quantitative ER status in predicting tumor response at surgery and to identify potential predictors of survival outcomes. METHODS: Univariate followed by multivariable regression analyses were conducted to assess the association between quantitative ER and tumor response assessed as tumor size reduction and pathologic complete response (pCR)...
May 2, 2017: Breast Cancer Research and Treatment
keyword
keyword
121072
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"